

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Madsen et al

Patent No.: 6,706,744 B2

Issued: March 16, 2004

Application No.: 09/996,023

Filed: November 16, 2001

For: Glucagon Antagonists/Inverse Agonists

**RESPONSE TO UNITED STATES PATENT OFFICE DECISION OF JULY 13, 2007**  
**CONCERNING CERTIFICATE OF CORRECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The United States Patent and Trademark Office in a Communication mailed July 13, 2007 has denied Applicants' June 20, 2007 request for a Certificate of Correction, stating that the requested corrections would change the meaning of the claims. In response to this decision, Applicants respectfully submit herewith a new Certificate of Correction. The Certificate of Correction submitted herewith requests corrections that were agreed upon by the undersigned and the Examiner for the above-identified application, Examiner Laura Stockton, in a telephone conversation on August 8, 2007.

Applicants request that The United States Patent and Trademark Office make the necessary changes and affirm that no new matter has been added.

Respectfully submitted,

Date: August 8, 2007

**/Richard W. Bork, Reg. No. 36,459/**  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE